PharmaCyte Biotech EBIT

PharmaCyte Biotech (PMCB) currently reports a EBIT of $-13M as of April 2026. That compares with $-4.4M in the prior-year period — down 192.8% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore PharmaCyte Biotech's EBIT history and peer comparisons.

PharmaCyte Biotech's EBIT decreased from $-4.4M to $-13M — a 192.8% year-over-year decrease (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PharmaCyte Biotech's EBIT of $-13M is lower than the Healthcare sector average of $22B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PharmaCyte Biotech reported $-13M in EBIT as of April 2026. That compares with $-4.4M in the prior-year period — down 192.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-13M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for PharmaCyte Biotech, and consider following PMCB for alerts when major investors trade the stock.